PD-0001 Can We Predict Time to Tumor Progression in Early Colorectal Cancer Patients Using CTCS Count?

Authors:

Abstract
Background: Colorectal cancer is the second most common cause of cancer-related death in Europe. Although significant improvements in the primary surgical and chemotherapeutic treatment, it has been estimated that approximately 30% of colorectal cancer patients develop metastases and die. Haematogenous spreading of tumor cells is a pivotal step in the metastatic process. Circulating tumor cells (CTCs) have potential ability to enter the circulation, invade the target organs and subsequently form metastases. Data suggest that the CTCs count before treatment is an independent predictor of progression free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer, meanwhile their prognostic role in patients with early disease is uncertain.